A Phase II, Randomized, Open-Label, Three-Arm Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Subcutaneous Interferon Beta-1a (Rebif) in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis

Trial Profile

A Phase II, Randomized, Open-Label, Three-Arm Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Subcutaneous Interferon Beta-1a (Rebif) in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Alemtuzumab (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Sponsors Genzyme Corporation; Sanofi
  • Most Recent Events

    • 27 Jun 2017 Results of post hoc pooled analysis comparing efficacy of alemtuzumab and ocrelizumab based on number needed to treat (NNT) from CAMMS223,CARE-MS I, CARE-MS II and OPERA I and II studies,presented at the 3rd Congress of the European Academy of Neurology.
    • 28 Apr 2017 Results comparing efficacy of alemtuzumab and ocrelizumab based on number needed to treat (NNT) pooled analysis from CAMMS223,CARE-MS I, CARE-MS II and OPERA I and II studies, presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 28 Apr 2017 Results of safety and efficacy of alemtuzumab over 10 years from CAMMS223 study and their extension study presented at the 69th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top